A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries

• Published in: The Journal of dermatological treatment 2025-12, Vol.36 (1)
• Main Authors: Alfalasi, Amani, Ameen, Ahmed, Al Lafi, Atlal, El Gendi, Ayman, Saad, Waqas, Ismail, Ahmed, Al Naeem, Ayman, Goturu, Srikumar, Al-Ahmed, Nasser, Dayem, Hussein Abdel, Nanda, Arti, Tawdy, Amira, Alogayell, Lulwa, Iraqi, Mohamed, Abdul Hay, Nasser, El Enezi, Manar, Walkhinde, Subash, Kamal, Marwa, Aldhuhoori, Muna, Almesfer, Asem, Abd Elwhab, Amira, Al Hawsawi, Khalid Ali, Barakat, Ahmad, Chmayse, Sahar, Hafiz, Mohammed, Chouikrat, Zahir, Fahmy, Monica
• Format: Article
• Language: English
• Subjects: ADCT; Atopic dermatitis; dupilumab; gulf; itch; real-world evidence
• ISSN: 0954-6634; 1471-1753
• DOI: 10.1080/09546634.2024.2443110

Purpose/aim of the study There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries.Materials and methods This observational study included patients with moderate-to-severe AD who initiated dupilumab within 30 days. Disease control, itching/pruritus, and patient satisfaction were assessed using Scoring Atopic Dermatitis (SCORAD), AD Control Tool (ADCT), and Patient Global Assessment of Treatment Effect (PGATE) scores at weeks 4, 12, and 24.Results The study included 187 participants with a mean age of 33.6 years. After 24 weeks, 75.1% of patients achieved disease control (ADCT score